[RUN_AMAF] provider=lambda | model=deepseek-r1-671b
DEBUG: Initializing agent TabuSynth with provider=lambda, model=deepseek-r1-671b
DEBUG: Initializing agent Contextron with provider=lambda, model=deepseek-r1-671b
DEBUG: Initializing agent Visura with provider=lambda, model=deepseek-r1-671b
DEBUG: Initializing agent SummaCraft with provider=lambda, model=deepseek-r1-671b
DEBUG: Initializing agent TrendAnalyser with provider=lambda, model=deepseek-r1-671b
DEBUG: Initializing agent MCP with provider=lambda, model=deepseek-r1-671b
DEBUG: _chat called with provider=lambda, model=deepseek-r1-671b
DEBUG: Using OpenAI client.chat.completions.create() with model=deepseek-r1-671b
DEBUG: OpenAI API call successful, response type: <class 'openai.types.chat.chat_completion.ChatCompletion'>
DEBUG: _chat called with provider=lambda, model=deepseek-r1-671b
DEBUG: Using OpenAI client.chat.completions.create() with model=deepseek-r1-671b
DEBUG: OpenAI API call successful, response type: <class 'openai.types.chat.chat_completion.ChatCompletion'>
DEBUG: _chat called with provider=lambda, model=deepseek-r1-671b
DEBUG: Using OpenAI client.chat.completions.create() with model=deepseek-r1-671b
DEBUG: OpenAI API call successful, response type: <class 'openai.types.chat.chat_completion.ChatCompletion'>

=== FINAL SUMMARY ===

{
  "71724d7e-77ae-4c4c-be12-73ca0443372d": [
    "The increase was driven by: $80 million increase in Research and development funding (2018: $52m \u2192 2019: $132m), $5 million improvement in Other, net (2018: -$2m \u2192 2019: $3m), $7 million reduction in Patent costs losses (2018: -$8m \u2192 2019: -$1m), with additional contributions from EU Commission IPCEI grants in Italy/France, partially offset by Singapore fab start-up costs.",
    ""
  ],
  "75623d36-47ae-4801-9727-ee17b04cd8e5": [
    "The decrease was due to: $13 million decrease in Research and development funding (2017: $65m \u2192 2018: $52m), $1 million worse performance in Other, net (2017: -$1m \u2192 2018: -$2m), aligning with textual context citing reduced R&D grants.",
    ""
  ],
  "bc38890b-c504-46e2-9546-765af952bdc5": [
    "55",
    "million"
  ],
  "a3ea64bc-4447-4c0b-b76c-84575a3a0de2": [
    "83",
    "million"
  ],
  "33de3029-3056-4598-bdff-30d9be4f52c3": [
    "6.33",
    "million"
  ],
  "cd3367c7-d3bd-440c-8c51-90a6ee95cc77": [
    "67",
    "million"
  ]
}

=== LOGS (per-agent) ===
{'TabuSynth': {'cot': '**QID: 71724d7e-77ae-4c4c-be12-73ca0443372d - What led '
                      'to increase in other income, net of expenses in '
                      '2019?**  \n'
                      '- **Answer**: The increase was primarily driven by:  \n'
                      '  1. A $80 million increase in Research and development '
                      'funding (from $52m in 2018 to $132m in 2019)  \n'
                      '  2. A $5 million improvement in Other, net (from -$2m '
                      'in 2018 to $3m in 2019)  \n'
                      '  3. A $7 million reduction in Patent costs losses '
                      '(from -$8m to -$1m)  \n'
                      '- **Evidence**:  \n'
                      '  - Research and development funding: Row 3, Columns 1 '
                      'vs. 2 ($132 vs. $52)  \n'
                      '  - Other, net: Row 8, Columns 1 vs. 2 ($3 vs. -$2)  \n'
                      '  - Patent costs: Row 6, Columns 1 vs. 2 (-$1 vs. '
                      '-$8)  \n'
                      '- **Table Data Used**:  \n'
                      '  - 2019: Row 3/Col 1, Row 8/Col 1, Row 6/Col 1  \n'
                      '  - 2018: Row 3/Col 2, Row 8/Col 2, Row 6/Col 2  \n'
                      '- **Missing Information**: None  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: 75623d36-47ae-4801-9727-ee17b04cd8e5 - What led '
                      'to decrease in other income, net of expenses in '
                      '2018?**  \n'
                      '- **Answer**: The decrease from 2017 to 2018 (-$2m) was '
                      'primarily due to:  \n'
                      '  1. A $13 million decrease in Research and development '
                      'funding (from $65m in 2017 to $52m in 2018)  \n'
                      '  2. A $1 million worse performance in Other, net (from '
                      '-$1m in 2017 to -$2m in 2018)  \n'
                      '- **Evidence**:  \n'
                      '  - Research and development funding: Row 3, Columns 2 '
                      'vs. 3 ($52 vs. $65)  \n'
                      '  - Other, net: Row 8, Columns 2 vs. 3 (-$2 vs. -$1)  \n'
                      '- **Table Data Used**:  \n'
                      '  - 2018: Row 3/Col 2, Row 8/Col 2  \n'
                      '  - 2017: Row 3/Col 3, Row 8/Col 3  \n'
                      '- **Missing Information**: None  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: bc38890b-c504-46e2-9546-765af952bdc5 - What was '
                      'the other income, net of expenses in 2017?**  \n'
                      '- **Answer**: $55 million  \n'
                      '- **Evidence**: Row 9, Column 3 ("Other income and '
                      'expenses, net" for 2017)  \n'
                      '- **Table Data Used**: Row 9, Column 3  \n'
                      '- **Missing Information**: None  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: a3ea64bc-4447-4c0b-b76c-84575a3a0de2 - What is '
                      'the average Research and development funding?**  \n'
                      '- **Answer**: $83 million  \n'
                      '- **Evidence**:  \n'
                      '  - 2019: $132m (Row 3, Column 1)  \n'
                      '  - 2018: $52m (Row 3, Column 2)  \n'
                      '  - 2017: $65m (Row 3, Column 3)  \n'
                      '  - Average: (132 + 52 + 65) / 3 = 83  \n'
                      '- **Table Data Used**: Row 3, Columns 1-3  \n'
                      '- **Missing Information**: None  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: 33de3029-3056-4598-bdff-30d9be4f52c3 - What is '
                      'the average gain on sale of businesses and non-current '
                      'assets?**  \n'
                      '- **Answer**: $6.33 million  \n'
                      '- **Evidence**:  \n'
                      '  - 2019: $7m (Row 7, Column 1)  \n'
                      '  - 2018: $8m (Row 7, Column 2)  \n'
                      '  - 2017: $4m (Row 7, Column 3)  \n'
                      '  - Average: (7 + 8 + 4) / 3 ≈ 6.33  \n'
                      '- **Table Data Used**: Row 7, Columns 1-3  \n'
                      '- **Missing Information**: None  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: cd3367c7-d3bd-440c-8c51-90a6ee95cc77 - What is '
                      'the increase/ (decrease) in Research and development '
                      'funding from 2017 to 2019?**  \n'
                      '- **Answer**: $67 million increase  \n'
                      '- **Evidence**:  \n'
                      '  - 2017: $65m (Row 3, Column 3)  \n'
                      '  - 2019: $132m (Row 3, Column 1)  \n'
                      '  - Change: 132 - 65 = +67  \n'
                      '- **Table Data Used**: Row 3, Columns 1 and 3  \n'
                      '- **Missing Information**: None',
               'result': '**QID: 71724d7e-77ae-4c4c-be12-73ca0443372d - What '
                         'led to increase in other income, net of expenses in '
                         '2019?**  \n'
                         '- **Answer**: The increase was primarily driven '
                         'by:  \n'
                         '  1. A $80 million increase in Research and '
                         'development funding (from $52m in 2018 to $132m in '
                         '2019)  \n'
                         '  2. A $5 million improvement in Other, net (from '
                         '-$2m in 2018 to $3m in 2019)  \n'
                         '  3. A $7 million reduction in Patent costs losses '
                         '(from -$8m to -$1m)  \n'
                         '- **Evidence**:  \n'
                         '  - Research and development funding: Row 3, Columns '
                         '1 vs. 2 ($132 vs. $52)  \n'
                         '  - Other, net: Row 8, Columns 1 vs. 2 ($3 vs. '
                         '-$2)  \n'
                         '  - Patent costs: Row 6, Columns 1 vs. 2 (-$1 vs. '
                         '-$8)  \n'
                         '- **Table Data Used**:  \n'
                         '  - 2019: Row 3/Col 1, Row 8/Col 1, Row 6/Col 1  \n'
                         '  - 2018: Row 3/Col 2, Row 8/Col 2, Row 6/Col 2  \n'
                         '- **Missing Information**: None  \n'
                         '\n'
                         '---\n'
                         '\n'
                         '**QID: 75623d36-47ae-4801-9727-ee17b04cd8e5 - What '
                         'led to decrease in other income, net of expenses in '
                         '2018?**  \n'
                         '- **Answer**: The decrease from 2017 to 2018 (-$2m) '
                         'was primarily due to:  \n'
                         '  1. A $13 million decrease in Research and '
                         'development funding (from $65m in 2017 to $52m in '
                         '2018)  \n'
                         '  2. A $1 million worse performance in Other, net '
                         '(from -$1m in 2017 to -$2m in 2018)  \n'
                         '- **Evidence**:  \n'
                         '  - Research and development funding: Row 3, Columns '
                         '2 vs. 3 ($52 vs. $65)  \n'
                         '  - Other, net: Row 8, Columns 2 vs. 3 (-$2 vs. '
                         '-$1)  \n'
                         '- **Table Data Used**:  \n'
                         '  - 2018: Row 3/Col 2, Row 8/Col 2  \n'
                         '  - 2017: Row 3/Col 3, Row 8/Col 3  \n'
                         '- **Missing Information**: None  \n'
                         '\n'
                         '---\n'
                         '\n'
                         '**QID: bc38890b-c504-46e2-9546-765af952bdc5 - What '
                         'was the other income, net of expenses in 2017?**  \n'
                         '- **Answer**: $55 million  \n'
                         '- **Evidence**: Row 9, Column 3 ("Other income and '
                         'expenses, net" for 2017)  \n'
                         '- **Table Data Used**: Row 9, Column 3  \n'
                         '- **Missing Information**: None  \n'
                         '\n'
                         '---\n'
                         '\n'
                         '**QID: a3ea64bc-4447-4c0b-b76c-84575a3a0de2 - What '
                         'is the average Research and development '
                         'funding?**  \n'
                         '- **Answer**: $83 million  \n'
                         '- **Evidence**:  \n'
                         '  - 2019: $132m (Row 3, Column 1)  \n'
                         '  - 2018: $52m (Row 3, Column 2)  \n'
                         '  - 2017: $65m (Row 3, Column 3)  \n'
                         '  - Average: (132 + 52 + 65) / 3 = 83  \n'
                         '- **Table Data Used**: Row 3, Columns 1-3  \n'
                         '- **Missing Information**: None  \n'
                         '\n'
                         '---\n'
                         '\n'
                         '**QID: 33de3029-3056-4598-bdff-30d9be4f52c3 - What '
                         'is the average gain on sale of businesses and '
                         'non-current assets?**  \n'
                         '- **Answer**: $6.33 million  \n'
                         '- **Evidence**:  \n'
                         '  - 2019: $7m (Row 7, Column 1)  \n'
                         '  - 2018: $8m (Row 7, Column 2)  \n'
                         '  - 2017: $4m (Row 7, Column 3)  \n'
                         '  - Average: (7 + 8 + 4) / 3 ≈ 6.33  \n'
                         '- **Table Data Used**: Row 7, Columns 1-3  \n'
                         '- **Missing Information**: None  \n'
                         '\n'
                         '---\n'
                         '\n'
                         '**QID: cd3367c7-d3bd-440c-8c51-90a6ee95cc77 - What '
                         'is the increase/ (decrease) in Research and '
                         'development funding from 2017 to 2019?**  \n'
                         '- **Answer**: $67 million increase  \n'
                         '- **Evidence**:  \n'
                         '  - 2017: $65m (Row 3, Column 3)  \n'
                         '  - 2019: $132m (Row 3, Column 1)  \n'
                         '  - Change: 132 - 65 = +67  \n'
                         '- **Table Data Used**: Row 3, Columns 1 and 3  \n'
                         '- **Missing Information**: None',
               'raw': '**QID: 71724d7e-77ae-4c4c-be12-73ca0443372d - What led '
                      'to increase in other income, net of expenses in '
                      '2019?**  \n'
                      '- **Answer**: The increase was primarily driven by:  \n'
                      '  1. A $80 million increase in Research and development '
                      'funding (from $52m in 2018 to $132m in 2019)  \n'
                      '  2. A $5 million improvement in Other, net (from -$2m '
                      'in 2018 to $3m in 2019)  \n'
                      '  3. A $7 million reduction in Patent costs losses '
                      '(from -$8m to -$1m)  \n'
                      '- **Evidence**:  \n'
                      '  - Research and development funding: Row 3, Columns 1 '
                      'vs. 2 ($132 vs. $52)  \n'
                      '  - Other, net: Row 8, Columns 1 vs. 2 ($3 vs. -$2)  \n'
                      '  - Patent costs: Row 6, Columns 1 vs. 2 (-$1 vs. '
                      '-$8)  \n'
                      '- **Table Data Used**:  \n'
                      '  - 2019: Row 3/Col 1, Row 8/Col 1, Row 6/Col 1  \n'
                      '  - 2018: Row 3/Col 2, Row 8/Col 2, Row 6/Col 2  \n'
                      '- **Missing Information**: None  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: 75623d36-47ae-4801-9727-ee17b04cd8e5 - What led '
                      'to decrease in other income, net of expenses in '
                      '2018?**  \n'
                      '- **Answer**: The decrease from 2017 to 2018 (-$2m) was '
                      'primarily due to:  \n'
                      '  1. A $13 million decrease in Research and development '
                      'funding (from $65m in 2017 to $52m in 2018)  \n'
                      '  2. A $1 million worse performance in Other, net (from '
                      '-$1m in 2017 to -$2m in 2018)  \n'
                      '- **Evidence**:  \n'
                      '  - Research and development funding: Row 3, Columns 2 '
                      'vs. 3 ($52 vs. $65)  \n'
                      '  - Other, net: Row 8, Columns 2 vs. 3 (-$2 vs. -$1)  \n'
                      '- **Table Data Used**:  \n'
                      '  - 2018: Row 3/Col 2, Row 8/Col 2  \n'
                      '  - 2017: Row 3/Col 3, Row 8/Col 3  \n'
                      '- **Missing Information**: None  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: bc38890b-c504-46e2-9546-765af952bdc5 - What was '
                      'the other income, net of expenses in 2017?**  \n'
                      '- **Answer**: $55 million  \n'
                      '- **Evidence**: Row 9, Column 3 ("Other income and '
                      'expenses, net" for 2017)  \n'
                      '- **Table Data Used**: Row 9, Column 3  \n'
                      '- **Missing Information**: None  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: a3ea64bc-4447-4c0b-b76c-84575a3a0de2 - What is '
                      'the average Research and development funding?**  \n'
                      '- **Answer**: $83 million  \n'
                      '- **Evidence**:  \n'
                      '  - 2019: $132m (Row 3, Column 1)  \n'
                      '  - 2018: $52m (Row 3, Column 2)  \n'
                      '  - 2017: $65m (Row 3, Column 3)  \n'
                      '  - Average: (132 + 52 + 65) / 3 = 83  \n'
                      '- **Table Data Used**: Row 3, Columns 1-3  \n'
                      '- **Missing Information**: None  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: 33de3029-3056-4598-bdff-30d9be4f52c3 - What is '
                      'the average gain on sale of businesses and non-current '
                      'assets?**  \n'
                      '- **Answer**: $6.33 million  \n'
                      '- **Evidence**:  \n'
                      '  - 2019: $7m (Row 7, Column 1)  \n'
                      '  - 2018: $8m (Row 7, Column 2)  \n'
                      '  - 2017: $4m (Row 7, Column 3)  \n'
                      '  - Average: (7 + 8 + 4) / 3 ≈ 6.33  \n'
                      '- **Table Data Used**: Row 7, Columns 1-3  \n'
                      '- **Missing Information**: None  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: cd3367c7-d3bd-440c-8c51-90a6ee95cc77 - What is '
                      'the increase/ (decrease) in Research and development '
                      'funding from 2017 to 2019?**  \n'
                      '- **Answer**: $67 million increase  \n'
                      '- **Evidence**:  \n'
                      '  - 2017: $65m (Row 3, Column 3)  \n'
                      '  - 2019: $132m (Row 3, Column 1)  \n'
                      '  - Change: 132 - 65 = +67  \n'
                      '- **Table Data Used**: Row 3, Columns 1 and 3  \n'
                      '- **Missing Information**: None'},
 'Contextron': {'cot': '**Question 1**: What led to increase in other income, '
                       'net of expenses in 2019?  \n'
                       '**Answer**: The increase was driven by:  \n'
                       '1. $80 million increase in Research and development '
                       'funding (2018: $52m → 2019: $132m)  \n'
                       '2. $5 million improvement in Other, net (2018: -$2m → '
                       '2019: $3m)  \n'
                       '3. $7 million reduction in Patent costs losses (2018: '
                       '-$8m → 2019: -$1m).  \n'
                       'Additionally, grants from European Commission IPCEI '
                       'programs in Italy/France contributed, partially offset '
                       'by Singapore fab start-up costs.  \n'
                       '**Source**: table-text  \n'
                       '**Type**: multi-span',
                'result': '**Question 2**: What led to decrease in other '
                          'income, net of expenses in 2018?  \n'
                          '**Answer**: The decrease was due to:  \n'
                          '1. $13 million decrease in Research and development '
                          'funding (2017: $65m → 2018: $52m)  \n'
                          '2. $1 million worse performance in Other, net '
                          '(2017: -$1m → 2018: -$2m).  \n'
                          'This aligns with the textual context citing reduced '
                          'R&D grants.  \n'
                          '**Source**: table-text  \n'
                          '**Type**: multi-span  \n'
                          '\n'
                          '**Question 3**: What was the other income, net of '
                          'expenses in 2017?  \n'
                          '**Answer**: $55 million  \n'
                          '**Source**: table-text (confirmed by both table Row '
                          '9/Col 3 and textual reference to "$55 million in '
                          '2017")  \n'
                          '**Type**: span  \n'
                          '\n'
                          '**Question 4**: What is the average Research and '
                          'development funding?  \n'
                          '**Answer**: $83 million  \n'
                          '**Source**: table (calculation: (132 + 52 + '
                          '65)/3)  \n'
                          '**Type**: arithmetic  \n'
                          '\n'
                          '**Question 5**: What is the average gain on sale of '
                          'businesses and non-current assets?  \n'
                          '**Answer**: $6.33 million  \n'
                          '**Source**: table (calculation: (7 + 8 + 4)/3)  \n'
                          '**Type**: arithmetic  \n'
                          '\n'
                          '**Question 6**: What is the increase/ (decrease) in '
                          'Research and development funding from 2017 to '
                          '2019?  \n'
                          '**Answer**: $67 million increase  \n'
                          '**Source**: table (132m - 65m)  \n'
                          '**Type**: arithmetic  \n'
                          '\n'
                          '---\n'
                          '\n'
                          '**Textual Context Summary for Downstream '
                          'Agents**:  \n'
                          'In 2019, other income increased to $103M (from $53M '
                          'in 2018) due to EU Commission IPCEI grants in '
                          'Italy/France, despite Singapore fab start-up costs. '
                          'In 2018, other income decreased to $53M (from $55M '
                          'in 2017) primarily from reduced R&D grants. All '
                          'figures are net of expenses and denominated in '
                          'millions of dollars.',
                'raw': '**Question 1**: What led to increase in other income, '
                       'net of expenses in 2019?  \n'
                       '**Answer**: The increase was driven by:  \n'
                       '1. $80 million increase in Research and development '
                       'funding (2018: $52m → 2019: $132m)  \n'
                       '2. $5 million improvement in Other, net (2018: -$2m → '
                       '2019: $3m)  \n'
                       '3. $7 million reduction in Patent costs losses (2018: '
                       '-$8m → 2019: -$1m).  \n'
                       'Additionally, grants from European Commission IPCEI '
                       'programs in Italy/France contributed, partially offset '
                       'by Singapore fab start-up costs.  \n'
                       '**Source**: table-text  \n'
                       '**Type**: multi-span  \n'
                       '\n'
                       '**Question 2**: What led to decrease in other income, '
                       'net of expenses in 2018?  \n'
                       '**Answer**: The decrease was due to:  \n'
                       '1. $13 million decrease in Research and development '
                       'funding (2017: $65m → 2018: $52m)  \n'
                       '2. $1 million worse performance in Other, net (2017: '
                       '-$1m → 2018: -$2m).  \n'
                       'This aligns with the textual context citing reduced '
                       'R&D grants.  \n'
                       '**Source**: table-text  \n'
                       '**Type**: multi-span  \n'
                       '\n'
                       '**Question 3**: What was the other income, net of '
                       'expenses in 2017?  \n'
                       '**Answer**: $55 million  \n'
                       '**Source**: table-text (confirmed by both table Row '
                       '9/Col 3 and textual reference to "$55 million in '
                       '2017")  \n'
                       '**Type**: span  \n'
                       '\n'
                       '**Question 4**: What is the average Research and '
                       'development funding?  \n'
                       '**Answer**: $83 million  \n'
                       '**Source**: table (calculation: (132 + 52 + 65)/3)  \n'
                       '**Type**: arithmetic  \n'
                       '\n'
                       '**Question 5**: What is the average gain on sale of '
                       'businesses and non-current assets?  \n'
                       '**Answer**: $6.33 million  \n'
                       '**Source**: table (calculation: (7 + 8 + 4)/3)  \n'
                       '**Type**: arithmetic  \n'
                       '\n'
                       '**Question 6**: What is the increase/ (decrease) in '
                       'Research and development funding from 2017 to 2019?  \n'
                       '**Answer**: $67 million increase  \n'
                       '**Source**: table (132m - 65m)  \n'
                       '**Type**: arithmetic  \n'
                       '\n'
                       '---\n'
                       '\n'
                       '**Textual Context Summary for Downstream Agents**:  \n'
                       'In 2019, other income increased to $103M (from $53M in '
                       '2018) due to EU Commission IPCEI grants in '
                       'Italy/France, despite Singapore fab start-up costs. In '
                       '2018, other income decreased to $53M (from $55M in '
                       '2017) primarily from reduced R&D grants. All figures '
                       'are net of expenses and denominated in millions of '
                       'dollars.'},
 'SummaCraft': {'cot': '(omitted)',
                'result': '{\n'
                          '  "71724d7e-77ae-4c4c-be12-73ca0443372d": [\n'
                          '    "The increase was driven by: $80 million '
                          'increase in Research and development funding (2018: '
                          '$52m \\u2192 2019: $132m), $5 million improvement '
                          'in Other, net (2018: -$2m \\u2192 2019: $3m), $7 '
                          'million reduction in Patent costs losses (2018: '
                          '-$8m \\u2192 2019: -$1m), with additional '
                          'contributions from EU Commission IPCEI grants in '
                          'Italy/France, partially offset by Singapore fab '
                          'start-up costs.",\n'
                          '    ""\n'
                          '  ],\n'
                          '  "75623d36-47ae-4801-9727-ee17b04cd8e5": [\n'
                          '    "The decrease was due to: $13 million decrease '
                          'in Research and development funding (2017: $65m '
                          '\\u2192 2018: $52m), $1 million worse performance '
                          'in Other, net (2017: -$1m \\u2192 2018: -$2m), '
                          'aligning with textual context citing reduced R&D '
                          'grants.",\n'
                          '    ""\n'
                          '  ],\n'
                          '  "bc38890b-c504-46e2-9546-765af952bdc5": [\n'
                          '    "55",\n'
                          '    "million"\n'
                          '  ],\n'
                          '  "a3ea64bc-4447-4c0b-b76c-84575a3a0de2": [\n'
                          '    "83",\n'
                          '    "million"\n'
                          '  ],\n'
                          '  "33de3029-3056-4598-bdff-30d9be4f52c3": [\n'
                          '    "6.33",\n'
                          '    "million"\n'
                          '  ],\n'
                          '  "cd3367c7-d3bd-440c-8c51-90a6ee95cc77": [\n'
                          '    "67",\n'
                          '    "million"\n'
                          '  ]\n'
                          '}',
                'raw': '```json\n'
                       '{\n'
                       '  "71724d7e-77ae-4c4c-be12-73ca0443372d": ["The '
                       'increase was driven by: $80 million increase in '
                       'Research and development funding (2018: $52m → 2019: '
                       '$132m), $5 million improvement in Other, net (2018: '
                       '-$2m → 2019: $3m), $7 million reduction in Patent '
                       'costs losses (2018: -$8m → 2019: -$1m), with '
                       'additional contributions from EU Commission IPCEI '
                       'grants in Italy/France, partially offset by Singapore '
                       'fab start-up costs.", ""],\n'
                       '  "75623d36-47ae-4801-9727-ee17b04cd8e5": ["The '
                       'decrease was due to: $13 million decrease in Research '
                       'and development funding (2017: $65m → 2018: $52m), $1 '
                       'million worse performance in Other, net (2017: -$1m → '
                       '2018: -$2m), aligning with textual context citing '
                       'reduced R&D grants.", ""],\n'
                       '  "bc38890b-c504-46e2-9546-765af952bdc5": ["55", '
                       '"million"],\n'
                       '  "a3ea64bc-4447-4c0b-b76c-84575a3a0de2": ["83", '
                       '"million"],\n'
                       '  "33de3029-3056-4598-bdff-30d9be4f52c3": ["6.33", '
                       '"million"],\n'
                       '  "cd3367c7-d3bd-440c-8c51-90a6ee95cc77": ["67", '
                       '"million"]\n'
                       '}\n'
                       '```'}}
